10375 related articles for article (PubMed ID: 1232535)
1. Active specific immunization in malignant melanoma.
Gercovich FG; Gutterman JU; Mavligit GM; Hersh EM
Med Pediatr Oncol; 1975; 1(3):277-87. PubMed ID: 1232535
[TBL] [Abstract][Full Text] [Related]
2. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer and specific active immunization of patients with malignant melanoma.
Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
[No Abstract] [Full Text] [Related]
4. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Berd D; Maguire HC; McCue P; Mastrangelo MJ
J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
[TBL] [Abstract][Full Text] [Related]
7. Immunocompetence, immunodeficiency and prognosis in cancer.
Hersh EM; Gutterman JU; Mavligit GM; Mountain CW; McBride CM; Brugess MA; Lurie PM; Zelen M; Takita H; Vincent RG
Ann N Y Acad Sci; 1976; 276():386-406. PubMed ID: 800324
[TBL] [Abstract][Full Text] [Related]
8. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy.
Golub SH; Forsythe AB; Morton DL
Int J Cancer; 1977 Jan; 19(1):18-26. PubMed ID: 137880
[TBL] [Abstract][Full Text] [Related]
9. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
10. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
Currie GA; McElwain TJ
Br J Cancer; 1975 Feb; 31(2):143-56. PubMed ID: 1164466
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
12. A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma.
Laucius JF; Bodurtha AJ; Mastrangelo JM; Bellet RE
Cancer; 1977 Nov; 40(5):2091-3. PubMed ID: 336181
[TBL] [Abstract][Full Text] [Related]
13. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
[No Abstract] [Full Text] [Related]
14. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
15. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
Mavligit GM; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
[TBL] [Abstract][Full Text] [Related]
16. Immunopathologic changes in patients with cutaneous malignant melanoma following intratumoral inoculation BCG: correlation with cell-mediated immunity.
Lieberman R; Epstein W; Fudenberg HH
Int J Cancer; 1974 Sep; 14(3):401-16. PubMed ID: 4617711
[No Abstract] [Full Text] [Related]
17. Immunotherapy of human malignant melanoma with irradiated tumor cells, oral Bacillus Calmette-Guérin, and levamisole.
Shibata HR; Jerry LM; Lewis MG; Mansell PW; Capek A; Marquis G
Ann N Y Acad Sci; 1976; 277(00):355-66. PubMed ID: 1069555
[No Abstract] [Full Text] [Related]
18. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.
Mitchell MS; Kan-Mitchell J; Kempf RA; Harel W; Shau HY; Lind S
Cancer Res; 1988 Oct; 48(20):5883-93. PubMed ID: 3262416
[TBL] [Abstract][Full Text] [Related]
19. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
20. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
[Next] [New Search]